Oliva EM et al. – In FY2008, prior to the Veterans Health Administration national mandate of access to buprenorphine Opioid agonist treatment (OAT), substantial variation in the use of OAT existed, partially explained by patient– and facility–level factors. Implementation efforts should focus on increasing access to this evidence–based treatment, especially in facilities at the low end of the distribution.
Register now to view all the MDLinx contents (FREE)!
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor